Indication: Advanced Solid Tumors
A Phase 1/2 Dose Escalation And Dose Expansion Study Of Ba3011 Alone And In Combination With Nivolumab In Adult And Adolescent Patients 12 Years And Older With Advanced Solid Tumors
Sub-indication: Miscellaneous Malignancies
Study Type: Drug Study
Principal Investigator: Jaspreet Grewal, M.D.Norton Cancer Institute
Sponsor: Sponsor: BioAtla LLC